{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
methyl salicylate
to a specific field?
Status:
Investigational
Source:
INN:dexproxibutene [INN]
Source URL:
Class (Stereo):
CHEMICAL (UNKNOWN)
Dexproxibutene is an experimental agent structurally related to propoxyphene. It is an analgesic agent. Dexproxibutene is not very effective in rheumatoid arthritis pain relief. It is intermediate in effectiveness between distalgesic, codis, aspirin and placebo.
Status:
Investigational
Source:
NCT00003713: Phase 1 Interventional Completed Unspecified Adult Solid Tumor, Protocol Specific
(1997)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Intoplicine is a pyrido[4,3-b]indole derivative patented by Rhone-Poulenc Sante as an antitumor agent. Intoplicine acts via inhibiting DNA nicking and closing reactions by stabilizing the cleavable complex, a transient intermediate in the religation reaction involving topoisomerase I and II and DNA. Intoplicine was active in a range of solid tumors in mice, including colon adenocarcinoma 51, MA16/C, MA14/A, MA13/C, early-stage pancreatic ductal adenocarcinoma 03, Glasgow osteogenic sarcoma and B16 melanoma. In Phase I clinical studies using a 24-h infusion, the maximum tolerated dose was established as 270 mg/m2 every 3 weeks, with hepatotoxicity rather than myelosuppression being dose-limiting, although cardiac toxicity was also seen. Preclinical cytotoxic concentrations were not achieved at the dose levels studied and clinical development was discontinued.
Class (Stereo):
CHEMICAL (ACHIRAL)
Nerbacadol is an analgesic agent.
Status:
Investigational
Source:
NCT02297425: Phase 2 Interventional Withdrawn Advanced EGFRm (Del 19 or L858R +/- T790M) NSCLC
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Class (Stereo):
CHEMICAL (UNKNOWN)
FENIMIDE, a succinimide derivative, is an antipsychotic drug. It is not found in any pharmaceutical preparations sold in the US. It was found that FENIMIDE produced a sedative effect prior to deeper central nervous system depression.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Esorubicin (4'-deoxydoxorubicin, NSC 267469) is a synthetic derivative of the anthracycline antineoplastic antibiotic doxorubicin with potential antineoplastic activity. Esorubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis. This agent exhibits less cardiotoxicity than the parent antibiotic doxorubicin, but may cause more severe myelosupression compared to other compounds within the anthracycline class. Esorubicin was being clinically tested for the treatment of solid tumors as well as lymphomas an leukemias. Esorubicin development has been discontinued.
Status:
Investigational
Source:
INN:nuclotixene [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Nuclotixene is an antidepressive agent.
Class (Stereo):
CHEMICAL (RACEMIC)
Bepafant (also known as WEB-2170), an inverse agonist of platelet-activating factor receptor that has been preclinical studied in asthma, Ischemic heart disorder and in reperfusion injury after orthotopic liver transplantation. However, these studies were discontinued. Besides, several experiments have shown that bepafant induced apoptosis in human acute myelogenous leukemia and thus could be the powerful antileukemic agent.
Status:
Investigational
Source:
INN:proxibutene [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Class (Stereo):
CHEMICAL (RACEMIC)
Tinisulpride is a sulfamoylbenzoic acid patented by Fabre, Pierre, S. A. as an antiemetic agent.
